- Aeon has closed a seed extension taking its total seed funding above $14 million and acquired the core assets of Germany’s Aware Health.
- The deal pairs Aeon’s whole-body MRI screening with Aware’s recurring blood diagnostics to build a longitudinal health record for customers.
- Aware previously raised $15 million in its own 2022 seed round, before being folded into Aeon’s German expansion.
Preventive healthcare has a data problem: most check-ups are a snapshot, not a picture that evolves over time. Zurich-based Aeon wants to change that. The company has closed a seed extension and acquired the core assets of Germany’s Aware Health, taking its total seed funding past $14 million.
The extension was co-led by Araya Ventures, with existing investors Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital and Bigwave Capital also participating. It builds on the €8.2 million seed round Aeon raised in June 2025.
Aeon was founded in 2023 by Tim Seithe, a physician who previously built and sold Tillhub to KKR-owned Unzer, alongside chief product officer Samuel Frey. The company combines whole-body MRI with blood diagnostics and AI, and has been live in Germany since early 2026 — already its fastest-growing market. The Aware acquisition adds recurring testing and established diagnostics infrastructure to that model.
“We are redefining preventive care by shifting it from reaction to action. Imaging tells you where you are. Blood diagnostics tell you where you are heading. AI is what connects the two into prediction. The acquisition of Aware Health accelerates that vision by two years, and this round gives us everything we need to execute,” said Seithe, founder and CEO of Aeon.
From MRI scans to recurring blood data
Whole-body MRI is powerful but episodic; blood testing can be repeated regularly. Combining the two gives Aeon longitudinal, multimodal health data to work with — repeated measurements rather than one-off readings — which it plans to use to flag deviations and eventually predict individual health risks.
More than 90% of Aeon’s check-ups already surface findings customers can act on, with a significant-finding rate of 15.4%. Those figures come from Aeon itself and haven’t been independently audited.
The acquisition brings a sizeable diagnostics infrastructure with it: Aware Health built a consumer blood-testing platform with more than 45 blood-draw locations, over 100 biomarkers, live laboratory integrations and nearly 10,000 active customers. TFN previously covered Aware’s $15 million seed round in 2022, when the Berlin startup was building a recurring blood-testing model to help consumers track health trends over time.
Ferdinand Schmidt-Thomé, co-founder of Aware Health, added: “What I am most proud of is what our team built at Aware: a trusted consumer health brand and a platform that made advanced diagnostics accessible and easy to understand. The acquisition gives what we built the opportunity to continue growing as part of a broader preventive-health offering. The combination with whole-body imaging and Aeon’s AI genuinely changes what preventive health looks like in Europe.”
Customer data will only transfer with each customer’s explicit consent, in line with GDPR.
AI becomes the third layer
Aeon is also expanding its AI team, with Pablo Tano joining as AI Lead. Tano is a computational neuroscientist who has published with Peter Dayan and Alexandre Pouget and was part of the team that won Meta’s MyoChallenge AI competition. At Aeon, he’ll lead models that read across imaging, blood biomarkers and genetic data to produce personalised risk predictions.
“Aeon is building something genuinely new in European healthcare. The combination of imaging, recurring blood diagnostics, and AI creates a longitudinal health picture that no other platform in Europe offers. We are proud to back Tim and the team at this moment,” said Rupa Popat, founder and managing partner at Araya Ventures.
A crowded European preventive-health race
Aeon is entering a market attracting serious capital. Zurich-based rival Ahead Health raised $10 million in July, seven months after a $6 million seed, also combining blood panels, whole-body MRI and AI as it expands into Germany and the Netherlands.
Paris-based Lucis has moved even faster: after an $8.5 million seed in December 2025, it raised a $20 million Series A four months later, bringing its total to roughly $28 million. US-based Prenuvo has built its proposition around whole-body MRI, while Austin’s Function Health secured $450 million in growth financing and has expanded through acquisitions including Getlabs and SuppCo.
Against that backdrop, the Aware deal is less about adding another diagnostic service and more about buying time: recurring biomarker data, a German customer base, and laboratory infrastructure that would otherwise take years to build. Whether a seed-stage European company can out-execute better-funded rivals on the same thesis — MRI plus blood plus AI, repeated over time — is the question the next eighteen months will answer.
